The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Osteoporosis in Patients With Schizophrenia
Abstract
OBJECTIVE: Osteoporosis is regularly mentioned as a possible consequence of treatment with prolactin-increasing antipsychotic medications, but little is known about the prevalence and the degree of loss of bone mineral density in patients suffering from schizophrenia. The authors' goals were to investigate the association between schizophrenia and a decrease in bone mineral density and to get more insight into potential underlying pathophysiological mechanisms. METHOD: In a cross-sectional study, the authors used dual x-ray absorptiometry to determine bone mineral density of 75 inpatients and outpatients suffering from schizophrenia. All patients had been treated with antipsychotics for at least 1 year, and only patients between the ages of 19 and 50 were studied to exclude patients with age-related idiopathic osteoporosis. RESULTS: In men but not women with schizophrenia, bone mineral density was significantly lower than normal in the lumbar region. A comparison of loss of bone mineral density in male and female patients showed significant differences between the sexes. Bone mineral density showed a negative correlation with negative symptoms and Positive and Negative Syndrome Scale total score and a positive correlation with 25-hydroxy-vitamin D3 levels and body mass index in male patients. In female patients, a positive correlation between body mass index and bone mineral density was found. Exposure to prolactin-increasing antipsychotics was not related to bone mineral density. CONCLUSIONS: The male patients with schizophrenia in this study suffered from low bone density. This finding as well as other reports lend support to directing more attention to bone metabolism in patients with schizophrenia, although there is no universally accepted screening policy to identify individuals at high risk for osteoporosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Oral health status is a frequently disregarded health issue among SMI patients (498), with low rates of dental examination within the past 12 months (569,577-579).”
From Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care (2011) · cites this paper as [498]
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Kanis, J. А., & Kanis, J. А. (1994) · Osteoporosis International · doi:10.1007/bf01622200 · Cited by 2,532
Diagnosis of osteoporosis and assessment of fracture risk
Kanis, J. А. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08761-5 · Cited by 2,266
Webb, A. R., KLINE, L., & Holick, M. F. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-2-373 · Cited by 1,661
Environmental factors that influence the cutaneous production of vitamin D
Holick, M. F. (1995) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/61.3.638s · Cited by 771
The Use of Biochemical Markers of Bone Turnover in Osteoporosis
Delmas, P. D., Eastell, R., Garnero, P., Seibel, M. J., & Stepan, J. J. (2000) · Osteoporosis International · doi:10.1007/s001980070002 · Cited by 717
Garnero, P., Sornay-Rendu, E., Claustrat, B., & Delmas, P. D. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.8.1526 · Cited by 709
Empirical Assessment of the Factorial Structure of Clinical Symptoms in Schizophrenia
WHITE, L. E., Harvey, P. D., Opler, L. A., & Lindenmayer, J. (2010) · Psychopathology · doi:10.1159/000285058 · Cited by 362
Decreased Bone Density in Hyperprolactinemic Women
Klibanski, A., Neer, R. M., Beitins, I. Z., Ridgway, E. C., Zervas, N. T., & McArthur, J. W. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012253032605 · Cited by 358
Glaser, D. L., & Kaplan, F. S. (1997) · Spine · doi:10.1097/00007632-199712151-00003 · Cited by 308
de León, J., Verghese, C., Tracy, J. I., Josiassen, R. C., & Simpson, G. M. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)90008-6 · Cited by 279
Quantum concept of bone remodeling and turnover: Implications for the pathogenesis of osteoporosis
Parfitt, A. M. (1979) · Calcified Tissue International · doi:10.1007/bf02441211 · Cited by 275
Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden
Cantor-Graae, E., Nordström, L. G., & McNeil, T. F. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00114-6 · Cited by 261
Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects
Halbreich, U. M., Kinon, B. J., Gilmore, J. A., & Kahn, L. (2002) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00112-9 · Cited by 248
Osteoporosis: recent advances in pathogenesis and treatment
Cooper, C. C., & Aihie, A. (1994) · QJM · doi:10.1093/oxfordjournals.qjmed.a068917 · Cited by 233
The Epidemiology of Early Schizophrenia
Häfner, H., Maurer, K., Löffler, W., Fätkenheuer, B., der Heiden, W. A., Riecher‐Rössler, A., Behrens, S., & Gattaz, W. F. (1994) · The British Journal of Psychiatry · doi:10.1192/s0007125000292714 · Cited by 221
Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies
Kanis, J. A., Johnell, O., Odén, A., Laet, C. E. D. H. D., Jönsson, B., & Dawson, A. (2002) · Bone · doi:10.1016/s8756-3282(01)00653-6 · Cited by 209
Decreased Bone Mineral Density in Medicated Psychiatric Patients
Halbreich, U. M., Rojansky, N., Palter, S. F., Hreshchyshyn, M. M., Kreeger, J., Bakhai, Y., & Rosan, R. C. (1995) · Psychosomatic Medicine · doi:10.1097/00006842-199509000-00011 · Cited by 193
Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients
Licinio, J., Seibyl, J. P., Altemus, M., Charney, D. S., & Krystal, J. H. (1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.9.1408 · Cited by 185
Substance Misuse in Patients with Schizophrenia
Kavanagh, D. J., McGrath, J. J., Saunders, J. B., Dore, G. M., & Clark, D. (2002) · Drugs · doi:10.2165/00003495-200262050-00003 · Cited by 156
Accelerated Osteoporosis in Psychiatric Patients: Possible Pathophysiological Processes
Halbreich, U. M., & Palter, S. F. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.3.447 · Cited by 119
Becker, D., Liver, O., Mester, R., Rapoport, M., Weizman, A., & Weiss, M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0704 · Cited by 107
Schweiger, U., Weber, B., Deuschle, M., & Heuser, I. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.118 · Cited by 101
Evaluation of the risk of hip fracture
Kanis, J. А., & McCloskey, E. V. (1996) · Bone · doi:10.1016/8756-3282(95)00493-9 · Cited by 74
Role of Ca2+ and vitamin D in the prevention and treatment of osteoporosis
Rodríguez-Martínez, M. A., & García-Cohen, E. C. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00164-x · Cited by 60
Bone mineral density and prolactin associations in patients with chronic schizophrenia
Abraham, G., Halbreich, U. M., Friedman, R. H., & Josiassen, R. C. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00321-8 · Cited by 48
Vitamin Therapy in the Absence of Obvious Deficiency
Ovesen, L. (1984) · Drugs · doi:10.2165/00003495-198427020-00003 · Cited by 40
Drug-Induced Metabolic Bone Disease
Wolinsky-Friedland, M. (1995) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30046-x · Cited by 35
Preventing and Treating Osteoporosis
Sherman, S. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb04020.x · Cited by 28
Therapies to improve bone mineral density and reduce the risk of fracture: clinical trial results.
Watts, N. B. (2002) · PubMed · Cited by 19
Research works printed but not linked: 1
- Bergemann N, Auler B, Parzer P, Resch F, Mundt C, Ziegler R, Seibel M: High bone turnover but normal bone mineral density in women with schizophrenia (abstract). Bone 2001; 28:248
Cited by
Sorted by citations
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
“Some studies (490493) found a relationship between the use of prolactin-raising medication and low BMD in patients with chronic schizophrenia, while others (474,489,494-498) failed to find a relationship between prolactin, AP and osteoporosis.”
BackgroundPhysical illness and schizophrenia: a review of the literature
Leucht, S., Burkard, T., Henderson, J., Maj, M., & Sartorius, N. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.01095.x · Cited by 633
World Journal of Pharmaceutical Sciences
(2021) · World Journal of Pharmaceutical Sciences · doi:10.54037/wjps · Cited by 246
Antipsychotic‐Induced Hyperprolactinemia
Bostwick, J. R., Guthrie, S. K., & Ellingrod, V. L. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.1.64 · Cited by 237
Secondary Effects of Antipsychotics: Women at Greater Risk Than Men
Seeman, M. V. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn023 · Cited by 184
“What the investigators found was that the body mass index (BMI) correlated positively with BMD: the more weight, the denser the bone in both sexes.(6) Howard et al.”
Background
Metadata
- Authors
- Hummer, M., Malik, P., Gasser, R. W., Hofer, A., Kemmler, G., Moncayo Naveda, R. C., Rettenbacher, M. A., & Fleischhacker, W. W.
- Affiliations
- Innsbruck Medical University (AT)
- Venue
- American Journal of Psychiatry
- Published
- 2005-01-01
- Volume
- 162
- Issue
- 1
- Pages
- 162-167
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2110298944
- Cited by
- 125
- References
- 30
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 4 · 2022: 2 · 2021: 4 · 2020: 1 · 2019: 4 · 2018: 6 · 2017: 6 · 2016: 6 · 2015: 7 · 2014: 7 · 2013: 6 · 2012: 7
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
- Keywords
- osteoporosis, schizophrenia, bone mineral density, antipsychotic drugs, prolactin, sex differences, body mass index, 25-hydroxyvitamin D3, bone metabolism, negative symptoms, bone loss
- MeSH terms
- Adult, Calcifediol, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Osteoporosis, Schizophrenia, Sex Factors, Antipsychotic Agents, Absorptiometry, Photon, Bone Density, Comorbidity, Body Mass Index, Sex Distribution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
